Biotech · Public company · Somerville, MA, US

Cue Biopharma, Inc.

Ticker CUE · SEC CIK 0001645460

Track this companyFree. Adds Cue Biopharma, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials53 recruiting or active

Pipeline programs3From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline3

CUE-101Phase 1 · Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
CUE-102Phase 1 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
KEYTRUDA®, PembrolizumabPhase 1 · Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026

CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCsPHASE2 · RECRUITING · started May 7, 2026ClinicalTrials.gov NCT07172256 · fetched Nov 12, 2026
CUE-102 in Recurrent GlioblastomaPHASE1 · ACTIVE_NOT_RECRUITING · started Jul 30, 2025ClinicalTrials.gov NCT06917885 · fetched Nov 12, 2026
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic CancersPHASE1 · COMPLETED · started Jun 14, 2022ClinicalTrials.gov NCT05360680 · fetched Nov 12, 2026
Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell CarcinomaPHASE2 · RECRUITING · started Dec 6, 2021ClinicalTrials.gov NCT04852328 · fetched Nov 12, 2026
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell CarcinomaPHASE1 · COMPLETED · started Jul 30, 2019ClinicalTrials.gov NCT03978689 · fetched Nov 12, 2026